Biggest Seed, Series A-E and Venture Investments within Oncology October 2023.
Download report here or view at the bottom of this page
October 2023 Snapshot:
170 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 137,568,830.00 total true investment received in USA and EU within the Oncology sector in October 2023 across 39 different biotechs.
Some Notable True Oncology Investments
✅Stramsen Biotech - $10,000,000 (Series A) : plant based medicines treating various cancers, infectious diseases and other illnesses
✅Actinium Pharmaceuticals - Undisclosed (Grant) : Radioimmunotherapy and Cell Therapy focusing in malignant Haem (AML) - PIIIx1, PIx4, Multiple preclinical.
✅ Actym Therapeutics - $25,500,000 (Series A): Preparing for Clinical Entry for a STING and IL-15 in Oncology.
✅ Shorla Pharma - $35,000,000 (Series B) : Phase III and 2x Phase I/II including both Solid and Non-Solid Oncology trials.
✅ Plus 20+ companies in the report.
Acquisitions
👉Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics BMS Press release, 8th October 2023
👉Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) Lilly press release, Oct 3rd 2023
👉 Clade Therapeutics (“Clade”) acquires Gadeta (Cell Therapy) - Clade Tx press release, 2nd October 2023
Full information on these acquisitions can be found in the report.
